<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430738</article-id><article-id pub-id-type="pmcid-ver">PMC12430738.1</article-id><article-id pub-id-type="pmcaid">12430738</article-id><article-id pub-id-type="pmcaiid">12430738</article-id><article-id pub-id-type="pmid">40540434</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002764</article-id><article-id pub-id-type="publisher-id">IJS-D-25-00024</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>CXCL13/CXCR5: a new target for pain treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="S">Shujun</given-names></name><degrees>MD</degrees><email>sunshujun-hust@foxmail.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="FT0002" ref-type="fn">
<sup>#</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="Y">Yan</given-names></name><degrees>MD</degrees><email>m201975873@hust.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="FT0002" ref-type="fn">
<sup>#</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="J">Jiwei</given-names></name><degrees>MD</degrees><email>sjw1120063516@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="FT0002" ref-type="fn">
<sup>#</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mao</surname><given-names initials="Z">Zhangyan</given-names></name><degrees>MD</degrees><email>maozhangyan@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="T">Tianhao</given-names></name><degrees>MD</degrees><email>m202175905@hust.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="Y">Yafen</given-names></name><degrees>MD</degrees><email>gaoyafen1030@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yang</surname><given-names initials="D">Dong</given-names></name><degrees>PhD</degrees><email>dongyang118@sina.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xiangdong</given-names></name><degrees>PhD</degrees><email>xiangdongchen2013@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-3051-0399</contrib-id><name name-style="western"><surname>Song</surname><given-names initials="G">Guobin</given-names></name><degrees>MD</degrees><email>sonngguobin@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</aff><aff id="aff2"><label>b</label>Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</aff><aff id="aff3"><label>c</label>Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of Education, China</aff><aff id="aff4"><label>d</label>Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Wuhan 430022, China. Tel.: +86 02785351606, Fax: +86 27 85351660, E-mail: <email>dongyang118@sina.com</email> (D. Yang); E-mail: <email>xiangdongchen2013@163.com</email> (X. Chen); E-mail: <email>sonngguobin@163.com</email> (G. Song).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6318</fpage><lpage>6329</lpage><history><date date-type="received"><day>01</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6318.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6318.pdf"/><abstract><p>Pain is a significant global health burden, and current treatments often fail to provide adequate relief due to an incomplete understanding of its mechanisms. This review integrates emerging evidence highlighting the CXCL13/CXCR5 chemokine pathway as a crucial mediator across various pain states, including nociceptive, inflammatory, and neuropathic pain. CXCL13 and CXCR5 are substantially upregulated in pain-related regions such as the spinal cord, dorsal root ganglia (DRG), and cerebrospinal fluid following nerve injury, inflammation, and in conditions like bone cancer or diabetes. The key mechanisms through which they contribute to pain include enhancing neuronal excitability by increasing Nav1.8 sodium channel currents in DRG neurons via p38 MAPK signaling, promoting neuroinflammation by activating NF-&#954;B, ERK, and JNK pathways, which drive the production of pro-inflammatory cytokines (e.g., TNF-&#945;, IL-6, IL-1&#946;) and immune cell infiltration, and activating glial cells, where CXCL13/CXCR5 signaling promotes astrocyte reactivity and indirectly activates microglia, thereby amplifying central sensitization. Genetic knockdown or pharmacological inhibition of CXCL13/CXCR5 has been shown to significantly reduce pain hypersensitivity in preclinical models. The pathway&#8217;s high tissue specificity in pain pathways and its multifaceted regulation of pain mechanisms make it a promising novel therapeutic target. Future research should address CXCL13/CXCR5 interactions with other pain-related pathways (e.g., CXCL12/CXCR4), explore non-GPCR signaling (e.g., &#946;-arrestins), and validate its potential as a clinical biomarker to guide targeted analgesic development.</p></abstract><kwd-group><kwd>CXCL13/CXCR5 pathway</kwd><kwd>glial cell</kwd><kwd>neuroinflammation</kwd><kwd>neuronal excitability</kwd><kwd>pain</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Pain, defined as &#8220;an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage&#8221; by the International Association for the Study of Pain<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>, is one of the most prevalent health problems in the modern world<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. It is a major cause of disability and depression, can lead to suicide, excruciates millions of people mentally and physically, and exerts an enormous socioeconomic burden, affecting over 30% of the global population according to recent studies<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>]</sup>. Neurobiologically, pain is generally categorized into three main forms: nociceptive pain, which is associated with the detection of potentially damaging noxious stimuli and serves a protective function; inflammatory pain, which is linked to tissue damage and the subsequent infiltration of immune cells, promoting repair through pain hypersensitivity until healing is complete; and pathological pain, resulting from damage to the nervous system or its abnormal functioning<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>. While there is overlap among these three types of pain within and between patients, treatment approaches are tailored to their distinct mechanisms. Over the past decade, substantial progress has been made by researchers in uncovering the genes, molecules, cells, and neural circuits that underlines the sensation of pain. However, the intricate mechanisms of pain remain largely enigmatic; discovering previously unidentified factors that mediate pain may pave the way for innovative therapeutic strategies in pain management.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>The CXCL13/CXCR5 signaling pathway is a pivotal mediator in diverse pain states (nociceptive, inflammatory, neuropathic), presenting a promising novel therapeutic target. Its consistent upregulation in key pain-processing regions (spinal cord, DRG, cerebrospinal fluid) correlates strongly with pain initiation and progression.</p></list-item><list-item><p>CXCL13/CXCR5 signaling drives pain through multifaceted mechanisms: modulating neuronal excitability (notably via Nav1.8 sodium channels and synaptic plasticity), promoting neuroinflammation (via NF-&#954;B, ERK, JNK, and pro-inflammatory cytokines), and activating glial cells (astrocytes and microglia).</p></list-item><list-item><p>Targeting CXCL13/CXCR5 offers potential advantages over existing targets (e.g., Nav1.7), leveraging its high tissue specificity in pain pathways and receptor selectivity to potentially minimize off-target effects. However, therapeutic development requires careful consideration of non-canonical signaling (e.g., &#946;-arrestins) and immune implications.</p></list-item><list-item><p>Critical future directions include: elucidating interactions with other pain-related pathways (e.g., CXCL12/CXCR4), defining its role as a pain biomarker, developing safe and effective pathway modulators, exploring combinatorial therapies, and advancing precision medicine approaches for personalized pain management.</p></list-item></list></p></sec></boxed-text></p><p>Chemokines, also known as chemotactic cytokines, constitute a sophisticated communication system utilized by all cell types, including immune cells, and are part of a family of heparin-binding proteins. Previous studies have demonstrated that chemokines are involved in a multitude of cellular responses, such as leukocyte chemotaxis and adhesion during tissue damage and infection<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. Furthermore, genetic studies have demonstrated that the chemokine system is connected to a broad spectrum of biological processes, including hematopoiesis, organogenesis, vascularization, and embryogenesis<sup>[<xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R8" ref-type="bibr">8</xref>]</sup>. Chemokines exert their effects on cells by activating surface receptors, which are predominantly seven-transmembrane-domain G-protein-coupled receptors expressed by leukocytes. Upon binding to these specific receptors, chemokines initiate signaling cascades that result in the rearrangement, change in shape, and migration of cells, particularly involving actin<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup>. Substantial evidence indicates that the involvement of various chemokine receptors and ligands is essential in numerous inflammatory diseases. Additionally, substantial evidence links the expression of a wide array of chemokine ligands and receptors is intimately linked to tumorigenesis<sup>[<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R11" ref-type="bibr">11</xref>]</sup>. The dysregulation of chemokines is also associated with the development of diabetes and obesity<sup>[<xref rid="R12" ref-type="bibr">12</xref>-<xref rid="R14" ref-type="bibr">14</xref>]</sup>. Moreover, the growing body of evidence from genetics, tissue analyses, and clinical studies indicates that chemokine-mediated etiologies are associated with diseases like asthma, rheumatoid arthritis, and sepsis<sup>[<xref rid="R14" ref-type="bibr">14</xref>-<xref rid="R18" ref-type="bibr">18</xref>]</sup>. Some studies have shown that chemoattractant receptors are among the most promising targets for anti-inflammatory drugs, particularly in the treatment of multiple sclerosis and so on<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>]</sup>. Recently, <italic toggle="yes">Science</italic> reported that C-X-C motif chemokine ligand 13 (CXCL13), which was initially discovered in stroma cells of B cell follicles regulating homing of B cells and a subset of T cells<sup>[<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>]</sup>, was elevated in aged dorsal root ganglia sensory neurons along with its specific receptor CXCR5 after injury, and CXCL13 neutralization reversed the regenerative decline and promoted neurological functional recovery after sciatic nerve injury<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup>. Moreover, latest studies have found that the chemokine CXCL13/CXCR5 signaling pathway plays a crucial role in a variety of pain models, including nerve injury, inflammation, bone cancer, drug related pain, as presented in Fig. <xref rid="F1" ref-type="fig">1</xref>. And these studies shows that the expression and function of CXCL13/CXCR5 in pain-related regions correlate with the initiation and progression of pain, indicating a significant role in pain sensation and transmission, and emphasizing the multifaceted action of CXCL13/CXCR5 in nociceptive, inflammatory, and pathological pain. Taken together, these latest findings show that CXCL13/CXCR5 signaling maybe a new discovery of a previously unrecognized target in pain<sup>[<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>]</sup>. Taken together, these findings suggest that CXCL13/CXCR5 signaling may represent a previously unrecognized therapeutic target in pain. Therefore, investigating the mechanisms of CXCL13/CXCR5 in pain is needed; insights gained could deepen our understanding of pain complexity and be exploited in future therapies.<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Schematic representation of CXCL13/CXCR5 pathway involving in different pain models through distinct mechanisms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6318-g001.jpg"/><attrib>Note: This figure depicts the latest findings of the unrecognized role of CXCL13 and its receptor CXCR5 in different pain models involved of nerve injury, chronic ischemia, malignant tumor, autoimmune disease and drug related pain, and so on. CXCL13/CXCR5 influences pain via alterations in neuronal excitability, neuroinflammation, and regulating of interaction of glial cells. Besides, CXCL13/CXCR5 also plays a crucial role in recruitment of T cells, activation of p38, pERK, JNK, MAPK, NF-&#954;B, pAKT and the expression TNF-&#945;, IL-6, IL-1&#946;, leading to the development and maintenance of pain.</attrib></fig>
</p><p>A systematic literature search was conducted using PubMed, Web of Science, and Scopus databases without time limits, with the final search conducted on 25 April 2025. Keywords included combinations of &#8220;CXCL13,&#8221; &#8220;CXCR5,&#8221; &#8220;pain,&#8221; &#8220;neuroinflammation,&#8221; &#8220;neuronal excitability,&#8221; and &#8220;synaptic plasticity.&#8221; Inclusion criteria prioritized peer-reviewed original research articles, preclinical studies, and clinical trials. Exclusion criteria removed reviews, editorials, and studies unrelated to pain mechanisms. Based on these criteria, we synthesized 517 articles for this review and highlight the latest progress in understanding the mechanisms of the CXCL13/CXCR5 signaling pathway in nociceptive, inflammatory, and pathological pain. We focused on how CXCL13/CXCR5 influences pain through changes in neuronal excitability, neuroinflammation, and glial cells. This review clarifies the distinct roles of CXCL13/CXCR5 in various regions and pain models, offering valuable insights and potential targets for the development of future pain therapeutics. This review was conceived and executed entirely by human investigators. No generative artificial intelligence tools were utilized for content creation, text generation, data interpretation, or logical reasoning. All analytical processes, result validations, and scholarly conclusions were derived through manual processes and expert scrutiny, in compliance with the TITAN Guidelines 2025<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup>.</p></sec><sec sec-type="intro"><title>The overview of CXCL13/CXCR5 pathway</title><p>Chemokines, a family of over 50 small secreted proteins, are renowned for regulating the trafficking of circulating immune cells, contributing to neuronal cell development, and being implicated in the pathogenesis of various inflammatory diseases<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. Traditionally, the chemokine family has been divided into four distinct subfamilies-CXC or &#945; subfamily, CC or &#946; subfamily, CX3C or &#948; subfamily, and C or &#947; subfamily-based on structural differences and the number of conserved N-terminal cysteine<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup>. The CXC family, characterized by a single amino acid residue interposed between the first two canonical cysteines forming a C-X-C motif, is one of the main chemokine subfamilies<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. This family encompasses 17 members, some of which possess the ELR motif (Glu-Leu-Arg) at their N-terminus. CXC-Chemokines exert their biological activities through specific receptors, named according to their chemokine subfamily classification, with seven CXC receptors currently identified (CXCR1 to CXCR8)<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. Notably, a prominent feature of many chemokines and their receptors is their promiscuity: some chemokines bind to multiple receptors, and some receptors exhibit overlapping ligand specificities with variable affinities, sometimes mediating diverse functions. For instance, both CXCL13 and CCL19 serve as ligands for CXCR5, and CXCL13 can also bind CXCR3<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup>. Thus, this promiscuity explains the broadly overlapping functions of many chemokines but adds complexity to regulating chemokine action. Emerging data indicate that certain chemokines, including CXCL5, CXCL10, CCL21, and CXCL13, are closely associated with acute and/or chronic pain<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R30" ref-type="bibr">30</xref>-<xref rid="R32" ref-type="bibr">32</xref>]</sup>. Although recent pain-related studies have highlighted the importance of the CXCL13/CXCR5 axis in physiological and pathological conditions, the mechanisms and characteristics of this pathway in pain pathogenesis still require comprehensive summarization and discussion.</p><p>CXCL13, also known as B lymphocyte chemoattractant (BLC), was originally identified in stromal cells in B cell follicles as regulating B cells migration and subsets of T cells through its interaction with the receptor CXCR5<sup>[<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>]</sup>. Recent evidence shows that CXCL13 is expressed in the brain and spinal cord under pathological conditions, such as multiple sclerosis (MS), autoimmune demyelination, primary CNS lymphoma, and chronic pain<sup>[<xref rid="R32" ref-type="bibr">32</xref>-<xref rid="R35" ref-type="bibr">35</xref>]</sup>. Furthermore, the expression levels of CXCL13 and CXCR5 are significantly increased in the sensory nervous system (including peripheral sensory ganglia and the spinal cord dorsal horn) after spinal nerve ligation (SNL). This upregulation contributes to neuron-glia crosstalk, neuroinflammation, and neuropathic pain development<sup>[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R36" ref-type="bibr">36</xref>]</sup>. Additionally, CXCL13/CXCR5 upregulation has been observed in animal models during the development and maintenance of inflammatory pain<sup>[<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R38" ref-type="bibr">38</xref>]</sup>. Furthermore, recent studies have found that an abnormal CXCL13/CXCR5 axis plays a crucial role in the pathogenesis of various pain types, including bone cancer, interstitial cystitis/bladder pain, remifentanil-induced hyperalgesia, and diabetes-induced tactile allodynia<sup>[<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R39" ref-type="bibr">39</xref>-<xref rid="R42" ref-type="bibr">42</xref>]</sup>. Knockdown of CXCL13 or knockout of CXCR5 reduces activation of inflammatory cascades and astrocytes in the spinal cord, thereby attenuating neuropathic pain<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup>. Collectively, these findings suggest a novel role for the CXCL13/CXCR5 signaling pathway in pain development, which was previously unidentified. This pathway represents a potential new therapeutic target for pain treatment.</p></sec><sec><title>The relationship between CXCL13/CXCR5 and pain</title><sec><title>Expression of CXCL13/CRCX5 in pain-related regions</title><p>CXCL13 was initially reported to be expressed exclusively in the brain and spinal cord under pathological conditions, not in the healthy central nervous system (CNS)<sup>[<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R43" ref-type="bibr">43</xref>]</sup>. However, recent studies have detected high expression levels of CXCL13 in lymph nodes and spleen, as well as low levels in the spinal cord and cerebrospinal fluid (CSF) of healthy humans<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup>. In addition, CXCL13 has been detected in the spinal cord of naive mice, with its expression upregulated following SNL. CXCL13 mRNA levels increase in the dorsal root ganglion (DRG) after local inflammation or peripheral nerve injury<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup>. Notably, among the 37 detectable chemokine genes upregulated by more than 3-fold after SNL, CXCL13 showed the most dramatic increase, with a 25.1-fold rise, compared to the 12.8-fold, 5.1-fold, and 3.3-fold increases in the levels of CCL7, CCL2, and CXCL1 genes, respectively<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup>. These findings indicate that CXCL13 is closely associated with the initiation and development of pain and may play a crucial role in the distinct mechanisms of central and peripheral pain.</p><p>CXCR5, also known as CD185 or Burkitt lymphoma receptor 1 (BLR1), is the primary receptor for CXCL13. CXCR5 is expressed on all B cells and a subset of T cells in blood, spleen, lymphatic tissue, and cerebrospinal fluid<sup>[<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref>]</sup>. The upregulated CXCL13 attracts B lymphocytes, some T cells, and macrophages via CXCR5 under pathological conditions<sup>[<xref rid="R48" ref-type="bibr">48</xref>]</sup>. Allodynia, hyperalgesia, and bone cancer pain induced by CXCL13 upregulation are reduced in CXCR5 knockout mice, suggesting CXCL13 contributes to pain pathogenesis via CXCR5.</p></sec><sec><title>Role of CXCL13/CXCR5 in pain</title><sec><title>CXCL13/CXCR5 pathway in nociceptive pain</title><p>The CXCL13/CXCR5 pathway plays a significant role in nociceptive pain. Local administration of CXCL13 induces thermal and mechanical pain hypersensitivity in a dose-dependent manner, an effect mitigated by CXCL13 inhibition or CXCL13 siRNA<sup>[<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R42" ref-type="bibr">42</xref>]</sup>. Alleviation of mechanical allodynia, thermal hyperalgesia, and spontaneous pain behavior by a CXCL13 neutralizing antibody 2 and 4&#160;hours post-dorsal horn ligation underscores CXCL13&#8217;s role in nociceptive pain pathogenesis<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>. Deletion or inhibition of CXCR5 persistently reduces pain hypersensitivity and thermal sensitivity in SNL mice<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup>. Intrathecal injections of recombinant CXCL13 (1&#160;&#956;g), IL-17 (400 ng), and the GluN2B selective antagonist Ro25-6981 (10&#160;&#956;g) ameliorate mechanical and thermal hyper-nociception following exogenous CXCL13 exposure<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup>. These findings collectively reveal that dysregulation of the CXCL13/CXCR5 pathway contributes to nociceptive pain.</p></sec><sec><title>CXCL13/CXCR5 pathway in inflammatory pain</title><p>CXCL13 and CXCR5 are crucial for the normal functioning of the immune system. However, under pathological conditions, their overexpression triggers the release of pro-inflammatory factors (e.g., IL-6, TNF-&#945;, IL-1&#946;, macrophage migration inhibitory factor), amplifying inflammatory signals and leading to immune responses and tissue damage<sup>[<xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R49" ref-type="bibr">49</xref>]</sup>. In experimental autoimmune cystitis mice, CXCL13 and CXCR5 upregulation correlates with significant increases in inflammatory cell infiltration, tissue apoptosis, inflammatory factors (IL-6, TNF-&#945;, and IL-1&#946;), and apoptosis-related proteins (Bax, caspase-3)<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup>. The CXCL13 selective inhibitor TAK-799 significantly improves bladder tissue apoptosis by reducing these inflammatory factors and attenuating apoptosis-related protein activation, ameliorating interstitial cystitis/bladder pain syndrome and improving bladder function<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup>. Chemokines also significantly mediate neuroinflammation and pain<sup>[<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R50" ref-type="bibr">50</xref>]</sup>. Tissue inflammation is associated with excitability of DRG sensory neurons, contributing to heat hyperalgesia and mechanical allodynia<sup>[<xref rid="R51" ref-type="bibr">51</xref>]</sup>. CXCL13 is produced by microglia, macrophages, endothelial cells after infection, and infiltrating dendritic cells in EAE mice<sup>[<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R53" ref-type="bibr">53</xref>]</sup>. Evidence shows that CXCL13 mRNA levels significantly increase in the DRG following local inflammation in mice<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup>. In rheumatoid arthritis pathogenesis, CXCL13 is produced by peripheral helper T cells accumulated in patient joints<sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup>. Heat hyperalgesia and mechanical allodynia induced by complete Freund&#8217;s adjuvant (CFA) inflammation are relieved in CXCR5-deficient mice. Furthermore, CFA inflammation enhances Nav1.8 sodium channel-mediated neuronal excitability in DRG neurons, which is reduced in CXCR5 knockout mice compared to wild type<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup>. CXCL13 incubation increases the response to ramp current stimulation in DRG neurons of wild type mice, but not in CXCR5 knockout mice<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup>. Collectively, these studies demonstrate that upregulated CXCL13/CXCR5 increases CFA-induced hyperexcitability of DRG neurons, crucial for maintaining inflammatory pain, as shown in Fig. <xref rid="F2" ref-type="fig">2</xref>. These results suggest the activated CXCL13/CXCR5 pathway mediates both the initiation and maintenance of inflammatory pain.<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Schematic representation of the CXCL13/CXCR5 pathway in mediating of pain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6318-g002.jpg"/><attrib>Note: This figure depicts the interaction between CXCL13 and its receptor CXCR5 in spinal cord neurons, highlighting their role in modulating neuronal excitability, neuroinflammation, activation of astrocytes, etc. in the context of pain. The upregulation of CXCL13 and CXCR5 in these neurons is associated with increased pain sensitivity through increasing the Nav 1.8, current amplitude and sEPSCs, and activation of neuroinflammation as indicated by the pathways involving pNF-&#954;B, IL-6, and other pro-inflammatory cytokines such as TNF-&#945; and IL-1&#946;. The figure also illustrates the involvement of PVT1, pERK, and IL-17 in the intracellular signaling cascades triggered by CXCL13/CXCR5 interaction, which may contribute to the development and maintenance of pain. The role of astrocytes and inflammatory cell infiltration in the neuroinflammatory response to pain is emphasized, along with the impact on tissue apoptosis factors such as the upregulation of Bax, Caspase-3, Caspase-8, and downregulation of Bcl-2, Bcl-XL, and Mcl-1. Abbreviations: spontaneous excitatory postsynaptic currents (sEPSCs), nuclear factor kappa-B (NF-&#954;B), tumor necrosis factor-alpha (TNF-&#945;), interleukin-1 beta (IL-1&#946;), interleukin-6 (IL-6), phospho-extracellular signal-regulated kinase (pERK), interleukin-17 (IL-17), mitogen-activated protein kinase (MAPK).</attrib></fig>
</p></sec><sec><title>CXCL13/CXCR5 pathway in pathological pain</title><p>Mounting evidence indicates the CXCL13/CXCR5 signaling pathway plays a vital role in pathological pain. Spinal cord levels of CXCL13 and CXCR5 positively correlate with neuropathic pain development and maintenance<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>.</p><p>In SNL mice and type 2 diabetes mice, CXCL13 increases in spinal cord neurons and CXCR5 in spinal astrocytes<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup>. Similar increases occur in the trigeminal ganglion following infraorbital nerve ligation<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup>. Pathological pain following infraorbital nerve ligation or spinal cord ligation is significantly attenuated in mice with CXCL13 or CXCR5 knockdown via shRNA<sup>[<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R44" ref-type="bibr">44</xref>]</sup>.</p><p>Microinjection of CXCL13 siRNA into the DRG mitigates mechanical allodynia and heat hyperalgesia induced by SNL<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>. Conversely, direct microinjection of CXCL13 protein into the L3/L4 DRGs of naive mice significantly induced heightened responses to mechanical and heat stimuli, indicating that CXCL13/CXCR5 contributes to pathological pain development.</p><p>Additionally, substantial evidence demonstrates the CXCL13/CXCR5 signaling axis contributes pivotally to the development and progression of several human cancers (e.g., bone, bladder, prostate, breast cancer)<sup>[<xref rid="R54" ref-type="bibr">54</xref>-<xref rid="R56" ref-type="bibr">56</xref>]</sup>.</p><p>However, recent evidence shows CXCL13/CXCR5 signaling not only modulates cancer cell growth, proliferation, invasion, and metastasis, but also contributes to neuropathic pain pathogenesis in cancer. Long noncoding RNA small nucleolar RNA host gene 5 (SNHG5) is involved in progression of multiple human cancers<sup>[<xref rid="R57" ref-type="bibr">57</xref>]</sup>. Recent studies identify CXCL13 as a novel downstream target of SNHG5, with CXCL13 levels positively correlating with SNHG5 levels in SNL mice<sup>[<xref rid="R58" ref-type="bibr">58</xref>]</sup>.</p><p>The initiation and maintenance of hyperalgesia in bone cancer pain rats is modulated by CXCL13, a downstream target of lncRNA NONRATT009773.2, highlighting CXCL13&#8217;s important role in cancer pain<sup>[<xref rid="R59" ref-type="bibr">59</xref>]</sup>. Exogenous murine recombinant CXCL13 protein injection substantially increases pain behavior incidence in a bone cancer pain model, an effect absent in bone cancer rats treated with CXCR5 inhibitors<sup>[<xref rid="R60" ref-type="bibr">60</xref>]</sup>, supporting CXCL13&#8217;s involvement in pathological pain activation via a CXCR5-dependent mechanism. These findings indicate that pathological pain is closely related to the CXCL13/CXCR5 signaling pathway, and that CXCL13 upregulation is sufficient to induce CXCR5-dependent neuropathic pain.</p></sec></sec></sec><sec><title>Mechanisms of CXCL13/CXCR5 pathway in pain</title><sec><title>CXCL13/CXCR5 pathway and neuronal excitability</title><p>Recent studies demonstrate that the CXCL13/CXCR5 pathway mediates excitatory synaptic transmission, amplifying neuronal sensation in both central and peripheral nervous systems. Expression of CXCL13 and CXCR5 increases in DRG neurons and in the anterior cingulate cortex (ACC) following intraplantar injection of complete Freund&#8217;s adjuvant (CFA) or SNL<sup>[<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R61" ref-type="bibr">61</xref>]</sup>. Voltage-gated sodium channels, particularly the tetrodotoxin-resistant sodium channel Nav 1.8, play a crucial role in regulating neuronal hyperexcitability, contributing to neuropathic and inflammatory pain<sup>[<xref rid="R54" ref-type="bibr">54</xref>-<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R62" ref-type="bibr">62</xref>]</sup>. Immunofluorescence double staining shows Nav1.8 highly co-expressed with CXCR5 in dissociated small- and medium-sized DRG neurons<sup>[<xref rid="R61" ref-type="bibr">61</xref>]</sup>, as shown in Fig. <xref rid="F3" ref-type="fig">3</xref>. Whole-cell patch-clamp recording reveals increased excitability of DRG neurons after CFA injection or CXCL13 incubation. The Nav1.8 current amplitude significantly increased in neurons treated with CXCL13 compared to vehicle, but not in DRG neurons from CXCR5 knockout mice. Furthermore, the neuronal excitability and hypersensitivity induced by CFA were significantly reduced in CXCR5 knockout mice<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup>. Intrathecal injection of Nav1.8 blocker attenuated CXCL13-induced pain hypersensitivity. Taken together, these results demonstrate that CXCL13 acts on CXCR5 in DRG neurons by increasing Nav1.8 current density in peripheral nerve system.<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Schematic representation of Nav1.8 channel contributing to neuronal hyperexcitability and pain hypersensitivity via CXCL13/CXCR5 pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6318-g003.jpg"/><attrib>Note: This figure depicted the expression of CXCL13 was increased in DRG neurons after intraplantar injection of CFA in peripheral inflammation. CFA and CXCL13 increased neuronal excitability through activation of Nav1.8 channel which was highly colocalized with CXCR5. Nav1.8 current density was increased via activation of p38 which was a downstream of CXCR5 in DRG. This figure shows that in increased expression of CXCL13 and CXCR5 in DRG neurons regulates Nav1.8 current density via p38 MAP kinase and further contributes to the neuronal hyperexcitability in inflammatory pain.</attrib></fig>
</p><p>Accumulating evidence establishes that ACC as a crucial brain region contributing to the emotional processing of pain in chronic pain models<sup>[<xref rid="R63" ref-type="bibr">63</xref>,<xref rid="R64" ref-type="bibr">64</xref>]</sup>. Neuroimaging studies show increased ACC activity during chronic pain, suppressed by ketamine in rats, potentially related to glutamatergic synaptic plasticity<sup>[<xref rid="R65" ref-type="bibr">65</xref>-<xref rid="R67" ref-type="bibr">67</xref>]</sup>. CXCL13 and CXCR5 expression and mRNA levels significantly increased in the ACC following SNL<sup>[<xref rid="R66" ref-type="bibr">66</xref>-<xref rid="R69" ref-type="bibr">69</xref>]</sup>. Electrophysiological recording from layer II-III ACC neurons showed that SNL increased the frequency and amplitude of spontaneous excitatory postsynaptic currents (sEPSCs). Application of CXCL13 (100&#160;ng/ml) increased sEPSC frequency and amplitude. Synaptic transmission in pyramidal neurons was attenuated in mice pre-injected with LV-Cxcr5 after SNL, consistent with reduced sEPSC frequency and amplitude<sup>[<xref rid="R61" ref-type="bibr">61</xref>]</sup>, indicating CXCL13 directly acts on neurons in neuropathic pain-related aversion via central synaptic potentiation. In behavioral tests, SNL-induced pain-related aversion was significantly reduced by LV-CXCR5 shRNA injection. These data suggest that CXCL13/CXCR5 contributes to pain-related aversion by increasing postsynaptic glutamatergic receptor-mediated excitatory synaptic transmission in the central nervous system<sup>[<xref rid="R61" ref-type="bibr">61</xref>]</sup>. Overall, these findings strongly support the key role of CXCL13/CXCR5 in regulating nociceptive neuron excitability in both the central and peripheral nervous systems.</p></sec><sec><title>CXCL13/CXCR5 pathway, neuroinflammation, and glial cells</title><sec><title>CXCL13/CXCR5 pathway and neuroinflammation</title><p>The CXCL13 gene is the most upregulated inflammation-related cytokine/chemokine across various pain models<sup>[<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref>]</sup>. Signal transducer and activator of transcription 3 (STAT3), a crucial transcription factor modulating chemokine/cytokine expression in the nervous system, is implicated in chronic pain<sup>[<xref rid="R70" ref-type="bibr">70</xref>]</sup>. Immunostaining revealed phosphorylated STAT3 (p-STAT3) co-localizes with CXCL13 in the spinal cord dorsal horn neurons of a chronic post-ischemic pain model, suggesting p-STAT3 contributes to chronic pain via the CXCL13/CXCR5 pathway. S3I-201, a specific STAT3 inhibitor, significantly reduced CXCL13 overproduction and alleviate mechanical allodynia in chronic post-ischemic pain mice<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup>.</p><p>Besides, mounting evidence indicates the CXCL13/CXCR5 pathway activates key intracellular signaling pathways, including NF-&#954;B, ERK, and JNK<sup>[<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R71" ref-type="bibr">71</xref>]</sup>. NF-&#954;B, a master transcription factor controlling pro-inflammatory genes (e.g., IL-6, CCL2, CCL3), regulates inflammation development. Phosphorylated NF-&#954;B (pNF-&#954;B) is co-expressed specifically in injured spinal neurons<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup>. <italic toggle="yes">Science</italic> reported that pNF-&#954;B drives CXCL13 overexpression in DRG sensory neurons after a sciatic nerve injury<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup>. CXCL13 attracted CD8+&#160;T cells to DRG neurons acting as antigen-presenting cells by overexpressing major histocompatibility complex class I (MHC I), leading to significant sensory neurological impairment compared to CXCR5&#8722;/&#8722; mice, as presented in Fig. <xref rid="F4" ref-type="fig">4</xref>. CXCL13 neutralization with monoclonal antibodies antagonized CXCR5+&#160;CD8+&#160;T cells recruitment to the DRG and alleviated post-injury neurological dysfunction. Intrathecal injection of the NF-&#954;B inhibitor pyrrolidine dithiocarbamate (PDTC) significantly reduced IL-6 levels and alleviated mechanical allodynia. Furthermore, intrathecal CXCL13 injection notably upregulated spinal cord pNF-&#954;B, a response absent in CXCR5 knockout mice<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup>. These findings support that the CXCL13/CXCR5 pathway modulates chronic pain by activating NF-&#954;B signaling and its downstream pro-inflammatory cytokine IL-6 in injured spinal neurons.<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Schematic representation of the activation of NF-&#954;B contributing to neuroinflammation via CXCL13/CXCR5 pathway in DRG sensory neurons after sciatic nerve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6318-g004.jpg"/><attrib>Note: This figure depicted that sciatic nerve injury induced the activation of NF-&#954;B in DRG which increased the expression of CXCL13 and mediated the recruitment of CXCR5+&#160;CD8+&#160;T cells into the DRG parenchyma. CXCR5+&#160;CD8+&#160;T cells engaged with MHC I presented by DRG neurons and affected the neurological function of sensory neurons in DRG.</attrib></fig>
</p><p>ERK is a significant CXCL13/CXCR5 signaling downstream effector in the spinal cord<sup>[<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R44" ref-type="bibr">44</xref>]</sup>. Western blot analysis demonstrated ERK activation by partial infraorbital nerve ligation (pIONL) and CFA, contributing to overexpression of pro-inflammatory cytokines (e.g., TNF-&#945;, IL-1&#946;). However, ERK, TNF-&#945;, and IL-1&#946; expression did not increase in CXCR5 knockout mice<sup>[<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R44" ref-type="bibr">44</xref>]</sup>, suggesting ERK induces CXCR5-dependent TNF-&#945; and IL-1&#946; expression. Furthermore, CXCL13 expression was observed in bladder epithelial cells, submucosa, and muscle after CFA treatment in experimental autoimmune cystitis mice, paralleling interstitial cystitis/bladder pain syndrome (IC/BPS) damage characterized by epithelial injury, JNK activation, inflammatory cell infiltration, tissue apoptosis, and the presence of inflammatory factors (IL-6, TNF-&#945;, and IL-1&#946;)<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup>. The CXCL13/CXCR5 axis blocker TAK-779 significantly reduced JNK activation, bladder inflammatory injury, and epithelial cell apoptosis<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup>, indicating JNK signaling pathway may be an important CXCL13/CXCR5 downstream pathway mediating inflammation-related pain and apoptosis in autoimmune diseases<sup>[<xref rid="R63" ref-type="bibr">63</xref>-<xref rid="R65" ref-type="bibr">65</xref>]</sup>.</p></sec><sec><title>CXCL13/CXCR5 pathway and glial cells</title><p>A growing body of evidence indicates CXCL13-CXCR5 interaction mediates neuron-glial cell communication in neuropathic pain. Spinal cord astrocyte activation (identified by glial fibrillary acidic protein, GFAP) was significantly diminished in CXCR5-deficient mice<sup>[<xref rid="R50" ref-type="bibr">50</xref>]</sup>. Conversely, GFAP-labeled astrocytes were notably increased with CXCL13 overexpression in spinal cord injury (SCI) mice or following intrathecal CXCL13 injection<sup>[<xref rid="R72" ref-type="bibr">72</xref>]</sup>. Downregulation of CXCL13 using recombinant lentivirus LV-sh-PVT1 significantly reduced astrocyte activation in SCI mice, improving neurological function and reducing hyperalgesia compared to controls. PVT1, highly expressed in T10 spinal cord of SCI rats and LPS-exposed astrocytes, showed significantly decreased IL-6, TNF-&#945;, and MDA expression upon its inhibition, reducing neuropathic pain incidence and spinal cord inflammatory responses. These findings suggest astrocyte activation, mediated by the CXCL13/CXCR5 signaling pathway, is crucial in neuropathic pain. Additionally, although CXCR5 is absent in spinal microglia, microglial activation was reduced in CXCR5-deficient mice after SNL<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup>. Moreover, upregulated CXCL13 increased expression of the microglial marker IBA-1 following astrocyte activation<sup>[<xref rid="R50" ref-type="bibr">50</xref>]</sup>, indicating microglial activation may occur via astrocyte-microglia interaction, as shown in Fig. <xref rid="F5" ref-type="fig">5</xref>. These data collectively imply that the CXCL13/CXCR5 pathway contributes to spinal cord pain development through glial cell activation.<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Schematic representation of spinal neuronal-glial interaction contributing to neuropathic pain after SNL via CXCL13/CXCR5 pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6318-g005.jpg"/><attrib>Note: This figure depicted that nerve injury induced robust neuronal expression of CXCL13 in spinal neurons after SNL, acted on its receptor CXCR5 in astrocytes and ipsilateral spinal neurons and contributed to nociceptive pain. CXCL13 was negatively regulated by miR-186-5p. The downregulation of miR-186-5P was mediated by NMDA receptor in spinal cord after nerve injury. CXCL13/CXCR5 mediated spinal neuronal-astrocytic interaction in neuropathic pain and activated astrocytes which regulated the activation of microglia by producing ATP and CCL2. Collectively, CXCL13 upregulation induced by downregulation of miR-186-5p after SNL activated astrocytes and induced the activation of microglia indirectly, leading to the upregulation of inflammatory cytokines such as IL-1&#946; and TNF-&#593; and further contributed to the mechanical allodynia and heat hyperalgesia in neuropathic pain.</attrib></fig>
</p></sec><sec><title>Relationship between CXCL13/CXCR5 pathway and other aspects</title><p>Reports indicate an absence of neuropathic pain in early life following peripheral nerve injury in rodents, although the specific prevalence in children remains undetermined<sup>[<xref rid="R67" ref-type="bibr">67</xref>-<xref rid="R69" ref-type="bibr">69</xref>]</sup>. Similar, nerve injury in infant rats fails to elicit neuropathic pain behavior until adolescence<sup>[<xref rid="R73" ref-type="bibr">73</xref>]</sup>. Research has reported that thymic stromal lymphopoietin (TSLP) facilitates T cell infiltration by inducing T cell regulators, such as CXCL13, during neuropathic pain development. These differences in neuropathic pain between adult and infant rats are attributed to varying expression levels of TSLP<sup>[<xref rid="R73" ref-type="bibr">73</xref>-<xref rid="R75" ref-type="bibr">75</xref>]</sup>.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Pain prevalence as a global health concern is rising, affecting up to 30% of the population and imposing significant personal and economic burden<sup>[<xref rid="R76" ref-type="bibr">76</xref>,<xref rid="R77" ref-type="bibr">77</xref>]</sup>. The inadequacy of current treatments (e.g., opioids, NSAIDs), often associated with side effects including gastric ulcers, kidney damage, and addiction<sup>[<xref rid="R78" ref-type="bibr">78</xref>,<xref rid="R79" ref-type="bibr">79</xref>]</sup>, that highlights the need for novel therapeutic approaches<sup>[<xref rid="R76" ref-type="bibr">76</xref>,<xref rid="R77" ref-type="bibr">77</xref>]</sup>. Traditional pain management primarily targets neuronal pain transduction and transmission, which may contribute to limited success in developing disease-modifying therapies<sup>[<xref rid="R80" ref-type="bibr">80</xref>-<xref rid="R82" ref-type="bibr">82</xref>]</sup>. Emerging evidence suggests pain processing involves glial cell activation, leukocyte infiltration, and inflammatory mediator production, indicating that targeting these pathways could deepen understanding and yield new therapeutic strategies.</p><p>This review synthesizes the roles of the CXCL13/CXCR5 pathway in various pain models, including mechanical nerve injury pain, post-ischemic pain, autoimmune-related pain, diabetes-related pain, remifentanil-induced hyperalgesia, inflammation pain, and cancer pain, as detailed in Table <xref rid="T1" ref-type="table">1</xref>. The CXCL13/CXCR5 pathway functions as a multifunctional regulator in various pain types, mediating pain through distinct mechanisms: regulating synaptic plasticity, activating neuron-glia/glia-neuron interactions, attracting leukocyte infiltration, and promoting inflammatory mediator production. The consistent upregulation of CXCL13/CXCR5 across pain models suggests a common pathway amenable to therapeutic targeting.
<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Role of CXCL13/CXCR5 in various pain models and their associated pathways</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Pain model</th><th align="center" rowspan="1" colspan="1">Chemokine/receptor</th><th align="center" rowspan="1" colspan="1">Distribution/cells</th><th align="center" rowspan="1" colspan="1">Upstream</th><th align="center" rowspan="1" colspan="1">Downstream</th><th align="center" rowspan="1" colspan="1">Diseases</th><th align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Spinal nerve ligation (SNL)/spared nerve injury (SNI)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">Spinal cord neurons &#8593;, T cells</td><td align="center" rowspan="1" colspan="1">miR-186-5p, TSLP, ZNF382</td><td align="center" rowspan="1" colspan="1">Recruitment of T cells, pERK, Activation of astrocyte</td><td align="left" rowspan="2" colspan="1">Nociceptive hypersensitivity, mechanical allodynia, Intractable neuropathic pain</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R83" ref-type="bibr">83</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="left" rowspan="1" colspan="1">Spinal astrocytes &#8593;, spinal cord neurons &#8593;, T cells, B cells</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Type 2 diabetes mice</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">Spinal cord neurons &#8593;</td><td align="center" rowspan="1" colspan="1">p-STAT3</td><td align="center" rowspan="1" colspan="1">pERK, pAKT, TNF-&#945;, IL-6</td><td align="left" rowspan="2" colspan="1">Painful diabetic neuropathy</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="left" rowspan="1" colspan="1">Spinal astrocytes &#8593;</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Infraorbital nerve ligation (trigeminal ganglion, TG)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">TG neurons &#8593;</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">pERK &#8593;, TNF-&#945;, IL-1&#946;</td><td align="left" rowspan="2" colspan="1">Orofacial mechanical allodynia</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="left" rowspan="1" colspan="1">TG neurons &#8593;</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Complete Freund&#8217;s Adjuvant (CFA)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">DRG neurons&#8593;</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">P38 MAPK, sodium channel Nav1.8, ERK MAPK</td><td align="left" rowspan="2" colspan="1">Inflammatory pain</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R84" ref-type="bibr">84</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="left" rowspan="1" colspan="1">DRG neurons&#8593;</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Chronic post-ischemic pain (CPIP)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">Neurons&#8593;</td><td align="center" rowspan="1" colspan="1">p-STAT3</td><td align="center" rowspan="1" colspan="1">/</td><td align="left" rowspan="2" colspan="1">Complex regional pain syndrome type-1</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="left" rowspan="1" colspan="1">Neurons&#8593;, astrocytes (partly &#8593;)</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">pNF-&#954;B&#8594;IL-6</td></tr><tr><td align="left" rowspan="2" colspan="1">Remifentanil-induced hyperalgesia (RIH)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="2" colspan="1">Spinal dorsal horn</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">IL-17/IL-17R, NMDA receptor</td><td align="left" rowspan="2" colspan="1">Hyperalgesia</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Experimental autoimmune cystitis (EAC)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="2" colspan="1">Bladder epithelial cells, submucosa and muscle</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">JNK, NF-&#954;B, IL-6, IL-1&#946;, TNF-&#945;</td><td align="left" rowspan="2" colspan="1">Interstitial cystitis/bladder pain syndrome</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Chronic compression injury (CCI)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="2" colspan="1">Spinal cord</td><td align="center" rowspan="1" colspan="1">IRF5</td><td align="center" rowspan="1" colspan="1">TNF-&#945;, IL-1&#946;, IL-6</td><td align="left" rowspan="2" colspan="1">Neuropathic pain</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R74" ref-type="bibr">74</xref>,<xref rid="R85" ref-type="bibr">85</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="2" colspan="1">Spinal cord injury (SCI)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="1" colspan="1">Astrocytes</td><td align="center" rowspan="1" colspan="1">miR-186-5p</td><td align="center" rowspan="1" colspan="1">COX2, iNOS, IL-6, IL-1&#946;, MDA</td><td align="left" rowspan="2" colspan="1">Neuropathic pain</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R86" ref-type="bibr">86</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="left" rowspan="1" colspan="1">Astrocytes</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Bone cancer pain (BCP)</td><td align="left" rowspan="1" colspan="1">CXCL13</td><td align="left" rowspan="2" colspan="1">Spinal cord</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">p-p38, p-ERK, p-AKT</td><td align="left" rowspan="2" colspan="1">Bone cancer or secondary bone metastasis</td><td align="center" rowspan="2" colspan="1"><sup>[<xref rid="R51" ref-type="bibr">51</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCR5</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Upregulation (&#8593;) indicates increased expression or activity in the specified cells or tissues.</p></fn><fn fn-type="abbr"><p>Abbreviations: thymic stromal lymphopoietin (TSLP), zinc finger protein 382 (ZNF382), dorsal root ganglia (DRG), mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), signal transducer and activator of transcription 3 (STAT3), N-methyl-D-aspartic acid (NMDA), interferon regulatory factor 5 (IRF5).</p></fn></table-wrap-foot></table-wrap>
</p><p>Despite extensive global research efforts, novel pain therapeutic development has seen limited success<sup>[<xref rid="R87" ref-type="bibr">87</xref>]</sup>, potentially due to pain mechanism complexity, translational gaps between animal models and humans, and lack of effective drug targets<sup>[<xref rid="R76" ref-type="bibr">76</xref>,<xref rid="R88" ref-type="bibr">88</xref>,<xref rid="R89" ref-type="bibr">89</xref>]</sup>. Compared to existing therapeutic targets for example Nav1.7, the CXCL13/CXCR5 axis regulates pain through multifaceted mechanisms, including modulation of neuronal excitability, neuroinflammation, and glia-neuron interactions. Furthermore, its high tissue specificity (CXCR5 is markedly upregulated in pain-associated regions) and receptor selectivity (CXCL13 primarily binds to CXCR5) significantly reduce off-target risks, thereby avoiding the central side effects and cardiotoxicity associated with traditional Nav1.7 inhibitors<sup>[<xref rid="R90" ref-type="bibr">90</xref>]</sup>. Therefore, the role of CXCL13/CXCR5 in pain warrants comprehensive investigation and may yield promising novel therapeutic targets.</p></sec><sec><title>Conclusion and perspectives</title><p>In conclusion, the CXCL13/CXCR5 signaling pathway is a critical mediator in pain pathophysiology, playing significant roles in nociceptive, inflammatory, and pathological pain. Its multifaceted involvement underscores strong potential as a therapeutic target. CXCL13 and CXCR5 expression in pain-related regions (spinal cord, DRG, cerebrospinal fluid) is closely associated with pain initiation and progression. Upregulation across diverse pain models suggests a common pathway amenable to therapeutic intervention.</p><p>The CXCL13/CXCR5 pathway influences pain through multimodal mechanisms: modulating neuronal excitability, neuroinflammation, and glial cell activation. Its interaction with voltage-gated sodium channels (particularly Nav1.8) and impact on synaptic plasticity in the central and peripheral nervous systems contribute to heightened pain sensitivity. Furthermore, this axis activates key intracellular signaling molecules (NF-&#954;B, ERK, JNK), implicated in pro-inflammatory cytokine production and neuroinflammation, a key driver of chronic pain. The pathway&#8217;s relationship with glial cells, particularly astrocytes and microglia, is also critical. CXCL13/CXCR5-mediated glial cell activation is increasingly recognized as essential for neuropathic pain development and maintenance, providing a novel avenue for therapeutic intervention through glial modulation. While CXCL13/CXCR5 is crucial in pain pathogenesis, CXCR5 signaling regulation remains poorly understood. Although CXCR5 was historically considered the sole receptor for CXCL13, recent research identifies CXCR3 as an additional receptor in ovarian cancer, Hashimoto&#8217;s thyroiditis, and drug-induced acute liver injury<sup>[<xref rid="R91" ref-type="bibr">91</xref>-<xref rid="R93" ref-type="bibr">93</xref>]</sup>, regulating CD4+&#160;T cell and/or macrophage function in peripheral T-cell lymphomas (PTCL). However, the roles of CXCL13/CXCR3 signaling axis in pain remains unexplored. Although some studies have shown that CXCL13/CXCR3 plays a role in common inflammatory disease pathways such as NF-&#954;B, its specific impact on pain is still unclear. In addition, recent studies show that &#946;-arrestins perform their functions at CXCR5<sup>[<xref rid="R94" ref-type="bibr">94</xref>]</sup>, indicating CXCL13 may act through non-classical signaling pathways other than G protein-coupled receptors. And this could be a research direction to regulate CXCL13 to exert analgesic effect in the future.</p><p>Notably, beyond CXCL13/CXCR5, other chemokines and their receptors, such as CXCL12/CXCR4, CXCL10/CXCR3, CXCL1/CXCR2, CCL2/CCR2 and CX3CL1/CX3CR1, are involved in the initiation and progression of pain<sup>[<xref rid="R92" ref-type="bibr">92</xref>-<xref rid="R97" ref-type="bibr">97</xref>]</sup>. For instance, the CXCL12/CXCR4 axis enhances neuronal excitability by activating DRG neurons, upregulating the phosphorylation of sodium channels (Nav1.8/Nav1.9), and promoting Ca<sup>2</sup><sup>+</sup> influx<sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup>. This process further triggers the release of pro-inflammatory cytokines (e.g., TNF-&#945;, IL-1&#946;), leading to pain sensitization<sup>[<xref rid="R99" ref-type="bibr">99</xref>]</sup>. Additionally, CXCL12/CXCR4 and CCL2/CCR2 axes could both activate downstream signaling pathways, including MAPK, ERK, and NF-&#954;B, resulting in central sensitization, neuroinflammation, and exacerbated pain transmission<sup>[<xref rid="R100" ref-type="bibr">100</xref>,<xref rid="R101" ref-type="bibr">101</xref>]</sup>. Crucially, current literature leaves unexplored whether the CXCL13/CXCR5 analgesic mechanism exhibits synergy with other pain-related pathways (e.g., CXCL12/CXCR4) or if cross-activation of inflammatory pathways involving NF-&#954;B, ERK, and JNK exists. Addressing these questions represents a critical frontier in pain research. Elucidating these mechanisms could reveal whether dual inhibition of CXCL13/CXCR5 and CXCL12/CXCR4 more effectively blocks pain signal cascade amplification, thereby guiding clinical strategies for pain management.</p><p>Looking forward, the CXCL13/CXCR5 axis serves as a biomarker in diverse clinical conditions, including tumor malignancy, autoimmune diseases, neurodegenerative disorders, and aging<sup>[<xref rid="R99" ref-type="bibr">99</xref>-<xref rid="R102" ref-type="bibr">102</xref>]</sup>. Its significant upregulation in DRG after SNL demonstrates strong potential as a pain biomarker<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>, though further validation across diverse pain models is required. Targeted therapies against the CXCL13/CXCR5 holds great promise for pain treatment, but challenges remain: pain mechanism complexity, the translational gap between animal models and humans, and the need for more precise drug targets. Current clinical applications targeting pain largely draw insights from studies on inflammation, autoimmune diseases, and cancer. Although the CXCL13/CXCR5 axis exhibits tissue specificity, its therapeutic modulation requires caution due to non-classical signaling mechanisms (e.g., &#946;-arrestins) and potential risks from chronic inhibition, such as impaired immune responses and increased infection susceptibility<sup>[<xref rid="R94" ref-type="bibr">94</xref>,<xref rid="R103" ref-type="bibr">103</xref>,<xref rid="R104" ref-type="bibr">104</xref>]</sup>. Thus, targeted interventions against this axis demand rigorous clinical evaluation to balance efficacy and safety. Future studies should focus on elucidating the specific roles of CXCL13/CXCR5 in different pain states, identifying biomarkers for patient stratification, and developing drugs that can safely and effectively modulate this pathway in humans. Additionally, the exploration of combinatorial therapies that target both the CXCL13/CXCR5 pathway and other related pain pathways may offer more effective pain management strategies. The potential synergistic effects of such combinations should be investigated to enhance the efficacy of pain treatment while minimizing side effects.</p><p>As understanding of the complex interplay between the immune system, neuronal excitability, and pain perception grows, so does hope for more effective and targeted pain management strategies. The future of pain research may lie in integrating immunological, neurological, and pharmacological approaches to develop next-generation therapies addressing pain&#8217;s multifaceted nature. This encompasses advancing precision medicine by tailoring treatments to individual genetic profiles and the specific mechanisms underlying pain, as well as devising non-invasive methods to accurately measure pain in animal models. Ultimately, the goal is to develop a holistic understanding of pain encompassing its biological, psychological, and social dimensions, enabling more effective and personalized management.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors gratefully acknowledge the contributions of all reviewers whose insightful feedback significantly enhanced the quality of this review paper.</p></ack><fn-group><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn id="FT0002"><label>
<sup>#</sup>
</label><p>These authors contributed equally to this work.</p></fn><fn fn-type="equal"><p>Published online 16 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>Funding for the research presented in the manuscript was provided by the following sources: the Fundamental Research Funds for the Central Universities (HUST: 2024JYCXJJ021), the National Natural Science Foundation (No. 82471251), and the Hubei Provincial Natural Science Foundation (No. 2023AFB761). The sponsors had no involvement in the study design; collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication.</p></sec><sec><title>Author contributions</title><p>S.S. and S.Y. wrote the main manuscript text. S.J. prepared the figures included in the manuscript. M.Z., D.Y., and G.Y. searched the literature and selected relevant articles for inclusion in the review. Y.D. revised and polished the manuscript to improve its quality and clarity. C.X. and S.G. proposed the research themes and coordinated the work within the group. All authors reviewed the manuscript and agreed on the journal to which the article should be submitted.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare no competing financial interests. There are no relevant financial or personal relationships that could inappropriately influence or bias the work presented in the manuscript. Examples such as employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding that could be perceived as conflicts of interest are not applicable in this case.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Guarantor</title><p>Guobin Song.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>Datasets generated during and/or analyzed during the current study are publicly available, and available upon reasonable request.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raja</surname><given-names>SN</given-names></name><name name-style="western"><surname>Carr</surname><given-names>DB</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The revised international association for the study of pain definition of pain: concepts, challenges, and compromises</article-title>. <source>Pain</source><year>2020</year>;<volume>161</volume>:<fpage>1976</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">32694387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000001939</pub-id><pub-id pub-id-type="pmcid">PMC7680716</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bushnell</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ceko</surname><given-names>M</given-names></name><name name-style="western"><surname>low</surname><given-names>LA</given-names></name></person-group>. <article-title>Cognitive and emotional control of pain and its disruption in chronic pain</article-title>. <source>Nat Rev Neurosci</source><year>2013</year>;<volume>14</volume>:<fpage>502</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">23719569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3516</pub-id><pub-id pub-id-type="pmcid">PMC4465351</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>SP</given-names></name><name name-style="western"><surname>Vase</surname><given-names>L</given-names></name><name name-style="western"><surname>Hooten</surname><given-names>WM</given-names></name></person-group>. <article-title>Chronic pain: an update on burden, best practices, and new advances</article-title>. <source>Lancet Lond Engl</source><year>2021</year>;<volume>397</volume>:<fpage>2082</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00393-7</pub-id><pub-id pub-id-type="pmid">34062143</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cj</surname><given-names>W</given-names></name></person-group>. <article-title>What is this thing called pain?</article-title><source>J Clin Invest</source><year>2010</year>;<volume>120</volume>:<fpage>3742</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">21041955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI45178</pub-id><pub-id pub-id-type="pmcid">PMC2965006</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rot</surname><given-names>A</given-names></name><name name-style="western"><surname>von Andrian</surname><given-names>UH</given-names></name></person-group>. <article-title>Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells</article-title>. <source>Annu Rev Immunol</source><year>2004</year>;<volume>22</volume>:<fpage>891</fpage>&#8211;<lpage>928</lpage>.<pub-id pub-id-type="pmid">15032599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.immunol.22.012703.104543</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagasawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>S</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1</article-title>. <source>Nature</source><year>1996</year>;<volume>382</volume>:<fpage>635</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">8757135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/382635a0</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>YR</given-names></name><name name-style="western"><surname>Kottmann</surname><given-names>AH</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development</article-title>. <source>Nature</source><year>1998</year>;<volume>393</volume>:<fpage>595</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">9634238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/31269</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Chemokines in homeostasis and diseases</article-title>. <source>Cell Mol Immunol</source><year>2018</year>;<volume>15</volume>:<fpage>324</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">29375126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2017.134</pub-id><pub-id pub-id-type="pmcid">PMC6052829</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>MT</given-names></name><name name-style="western"><surname>Luster</surname><given-names>AD</given-names></name></person-group>. <article-title>Chemokines in cancer</article-title>. <source>Cancer Immunol Res</source><year>2014</year>;<volume>2</volume>:<fpage>1125</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">25480554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-14-0160</pub-id><pub-id pub-id-type="pmcid">PMC4258879</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagarsheth</surname><given-names>N</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>MS</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W</given-names></name></person-group>. <article-title>Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</article-title>. <source>Nat Rev Immunol</source><year>2017</year>;<volume>17</volume>:<fpage>559</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">28555670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2017.49</pub-id><pub-id pub-id-type="pmcid">PMC5731833</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayaraj</surname><given-names>ND</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Belmadani</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Reducing CXCR4-mediated nociceptor hyperexcitability reverses painful diabetic neuropathy</article-title>. <source>J Clin Invest</source><year>2018</year>;<volume>128</volume>:<fpage>2205</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">29533926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI92117</pub-id><pub-id pub-id-type="pmcid">PMC5983349</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>JF</given-names></name><name name-style="western"><surname>England</surname><given-names>BR</given-names></name><name name-style="western"><surname>George</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source><year>2021</year>;<volume>80</volume>:<fpage>566</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">33397733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2020-219140</pub-id><pub-id pub-id-type="pmcid">PMC8928597</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loretelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Rocchio</surname><given-names>F</given-names></name><name name-style="western"><surname>D&#8217;Addio</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>The IL-8-CXCR1/2 axis contributes to diabetic kidney disease</article-title>. <source>Metabolism</source><year>2021</year>;<volume>121</volume>:<fpage>154804</fpage>.<pub-id pub-id-type="pmid">34097917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2021.154804</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gurish</surname><given-names>MF</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis</article-title>. <source>Nature</source><year>2017</year>;<volume>542</volume>:<fpage>110</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">28150777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature20810</pub-id><pub-id pub-id-type="pmcid">PMC5349321</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firestein</surname><given-names>GS</given-names></name><name name-style="western"><surname>McInnes</surname><given-names>IB</given-names></name></person-group>. <article-title>Immunopathogenesis of rheumatoid arthritis</article-title>. <source>Immunity</source><year>2017</year>;<volume>46</volume>:<fpage>183</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">28228278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2017.02.006</pub-id><pub-id pub-id-type="pmcid">PMC5385708</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>PJ</given-names></name></person-group>. <article-title>Targeting cytokines to treat asthma and chronic obstructive pulmonary disease</article-title>. <source>Nat Rev Immunol</source><year>2018</year>;<volume>18</volume>:<fpage>454</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">29626211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-018-0006-6</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saikumar Jayalatha</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hesse</surname><given-names>L</given-names></name><name name-style="western"><surname>Ketelaar</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention</article-title>. <source>Pharmacol Ther</source><year>2021</year>;<volume>225</volume>:<fpage>107847</fpage>.<pub-id pub-id-type="pmid">33819560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2021.107847</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Moldawer</surname><given-names>LL</given-names></name><name name-style="western"><surname>Opal</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Sepsis and septic shock</article-title>. <source>Nat Rev Dis Primer</source><year>2016</year>;<volume>2</volume>:<fpage>16045</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2016.45</pub-id><pub-id pub-id-type="pmcid">PMC5538252</pub-id><pub-id pub-id-type="pmid">28117397</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>TNC</given-names></name><name name-style="western"><surname>Power</surname><given-names>CA</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Chemokine blockers&#8211;therapeutics in the making?</article-title><source>Trends Pharmacol Sci</source><year>2006</year>;<volume>27</volume>:<fpage>41</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">16310864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2005.11.001</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foley</surname><given-names>JF</given-names></name><name name-style="western"><surname>Defer</surname><given-names>G</given-names></name><name name-style="western"><surname>Ryerson</surname><given-names>LZ</given-names></name><etal/></person-group>. <article-title>NOVA study investigators, comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial</article-title>. <source>Lancet Neurol</source><year>2022</year>;<volume>21</volume>:<fpage>608</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">35483387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(22)00143-0</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ansel</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>VN</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>PL</given-names></name><etal/></person-group>. <article-title>A chemokine-driven positive feedback loop organizes lymphoid follicles</article-title>. <source>Nature</source><year>2000</year>;<volume>406</volume>:<fpage>309</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">10917533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35018581</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>F&#246;rster</surname><given-names>R</given-names></name><name name-style="western"><surname>Mattis</surname><given-names>AE</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen</article-title>. <source>Cell</source><year>1996</year>;<volume>87</volume>:<fpage>1037</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">8978608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(00)81798-5</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Kong</surname><given-names>G</given-names></name><name name-style="western"><surname>Palmisano</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Reversible CD8 T cell-neuron cross-talk causes aging-dependent neuronal regenerative decline</article-title>. <source>Science</source><year>2022</year>;<volume>376</volume>:<fpage>eabd5926</fpage>.<pub-id pub-id-type="pmid">35549409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd5926</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>BC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>YJ</given-names></name></person-group>. <article-title>Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential</article-title>. <source>Pharmacol Ther</source><year>2020</year>:<volume>2</volume>:<fpage>107581</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2020.107581</pub-id><pub-id pub-id-type="pmid">32450191</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#233;lik Parsadaniantz</surname><given-names>S</given-names></name><name name-style="western"><surname>Rivat</surname><given-names>C</given-names></name><name name-style="western"><surname>Rost&#232;ne</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Opioid and chemokine receptor crosstalk: a promising target for pain therapy?</article-title><source>Nat Rev Neurosci</source><year>2015</year>;<volume>16</volume>:<fpage>69</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">25588373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3858</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of artificial intelligence &#8211; the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>1</volume>:<fpage>100082</fpage>.</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charo</surname><given-names>IF</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group>. <article-title>The many roles of chemokines and chemokine receptors in inflammation</article-title>. <source>N Engl J Med</source><year>2006</year>;<volume>354</volume>:<fpage>610</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">16467548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra052723</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asensio</surname><given-names>VC</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>IL</given-names></name></person-group>. <article-title>Chemokines in the CNS: plurifunctional mediators in diverse states</article-title>. <source>Trends Neurosci</source><year>1999</year>;<volume>22</volume>:<fpage>504</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">10529818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0166-2236(99)01453-8</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The role of CXCL family members in different diseases</article-title>. <source>Cell Death Discov</source><year>2023</year>;<volume>9</volume>:<fpage>212</fpage>.<pub-id pub-id-type="pmid">37393391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01524-9</pub-id><pub-id pub-id-type="pmcid">PMC10314943</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>CXCL5 activates CXCR2 in nociceptive sensory neurons to drive joint pain and inflammation in experimental gouty arthritis</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>3263</fpage>.<pub-id pub-id-type="pmid">38627393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-47640-7</pub-id><pub-id pub-id-type="pmcid">PMC11021482</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirth</surname><given-names>M</given-names></name><name name-style="western"><surname>Gandla</surname><given-names>J</given-names></name><name name-style="western"><surname>H&#246;per</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>CXCL10 and CCL21 promote migration of pancreatic cancer cells toward sensory neurons and neural remodeling in tumors in mice, associated with pain in patients</article-title>. <source>Gastroenterology</source><year>2020</year>;<volume>159</volume>:<fpage>665</fpage>&#8211;<lpage>681.e13</lpage>.<pub-id pub-id-type="pmid">32330476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.04.037</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>CXCL13 contributes to chronic pain of a mouse model of CRPS-I via CXCR5-mediated NF-&#954;B activation and pro-inflammatory cytokine production in spinal cord dorsal horn</article-title>. <source>J Neuroinflamm</source><year>2023</year>;<volume>20</volume>:<fpage>109</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-023-02778-x</pub-id><pub-id pub-id-type="pmcid">PMC10165831</pub-id><pub-id pub-id-type="pmid">37158939</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>JR</given-names></name><name name-style="western"><surname>Braziel</surname><given-names>RM</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma</article-title>. <source>Blood</source><year>2003</year>;<volume>101</volume>:<fpage>815</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">12393412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2002-05-1576</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagaeva</surname><given-names>LV</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P</given-names></name><name name-style="western"><surname>Powers</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis</article-title>. <source>J Immunol Baltim Md 1950</source><year>2006</year>;<volume>176</volume>:<fpage>7676</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.176.12.7676</pub-id><pub-id pub-id-type="pmid">16751415</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellebjerg</surname><given-names>F</given-names></name><name name-style="western"><surname>B&#246;rnsen</surname><given-names>L</given-names></name><name name-style="western"><surname>Khademi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS</article-title>. <source>Neurology</source><year>2009</year>;<volume>73</volume>:<fpage>2003</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">19996075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181c5b457</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>B-C</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D-L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5</article-title>. <source>J Clin Invest</source><year>2016</year>;<volume>126</volume>:<fpage>745</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">26752644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI81950</pub-id><pub-id pub-id-type="pmcid">PMC4731172</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X-B</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D-L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>CXCL13/CXCR5 enhances sodium channel Nav1.8 current density via p38 MAP kinase in primary sensory neurons following inflammatory pain</article-title>. <source>Sci Rep</source><year>2016</year>;<volume>6</volume>:<fpage>34836</fpage>.<pub-id pub-id-type="pmid">27708397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep34836</pub-id><pub-id pub-id-type="pmcid">PMC5052602</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B-C</given-names></name><etal/></person-group>. <article-title>ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons</article-title>. <source>J Exp Med</source><year>2021</year>;<volume>218</volume>:<fpage>e20210920</fpage>.<pub-id pub-id-type="pmid">34762123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20210920</pub-id><pub-id pub-id-type="pmcid">PMC8590274</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Activation of CXCL13/CXCR5 axis aggravates experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome</article-title>. <source>Biochem Pharmacol</source><year>2022</year>;<volume>200</volume>:<fpage>115047</fpage>.<pub-id pub-id-type="pmid">35452631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2022.115047</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ao</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer</article-title>. <source>Biochim Biophys Acta Rev Cancer</source><year>2022</year>;<volume>1877</volume>:<fpage>188799</fpage>.<pub-id pub-id-type="pmid">36103908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2022.188799</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>CXCL13/CXCR5 signaling contributes to diabetes-induced tactile allodynia via activating pERK, pSTAT3, pAKT pathways and pro-inflammatory cytokines production in the spinal cord of male mice</article-title>. <source>Brain Behav Immun</source><year>2019</year>;<volume>80</volume>:<fpage>711</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">31100371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2019.05.020</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>ST</given-names></name><name name-style="western"><surname>Yu</surname><given-names>WL</given-names></name><etal/></person-group>. <article-title>CXCL13 regulates the trafficking of GluN2B-containing NMDA receptor via IL-17 in the development of remifentanil-induced hyperalgesia in rats</article-title>. <source>Neurosci Lett</source><year>2017</year>;<volume>648</volume>:<fpage>26</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">28359934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2017.03.044</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Columba-Cabezas</surname><given-names>S</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis</article-title>. <source>J Neuroimmunol</source><year>2004</year>;<volume>148</volume>:<fpage>11</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">14975582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2003.10.056</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice</article-title>. <source>J Neuroinflamm</source><year>2016</year>;<volume>13</volume>:<fpage>1</fpage>-<lpage>3</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-016-0652-1</pub-id><pub-id pub-id-type="pmcid">PMC4940825</pub-id><pub-id pub-id-type="pmid">27401148</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strong</surname><given-names>JA</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>DE</given-names></name><etal/></person-group>. <article-title>Microarray analysis of rat sensory ganglia after local inflammation implicates novel cytokines in pain</article-title>. <source>PloS One</source><year>2012</year>;<volume>7</volume>:<fpage>e40779</fpage>.<pub-id pub-id-type="pmid">22815815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0040779</pub-id><pub-id pub-id-type="pmcid">PMC3397953</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>CH</given-names></name><name name-style="western"><surname>Rott</surname><given-names>LS</given-names></name><name name-style="western"><surname>Clark-Lewis</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Subspecialization of CXCR5+ T cells: b helper activity is focused in a germinal center-localized subset of CXCR5+ T cells</article-title>. <source>J Exp Med</source><year>2001</year>;<volume>193</volume>:<fpage>1373</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">11413192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.193.12.1373</pub-id><pub-id pub-id-type="pmcid">PMC2193300</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krumbholz</surname><given-names>M</given-names></name><name name-style="western"><surname>Theil</surname><given-names>D</given-names></name><name name-style="western"><surname>Cepok</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment</article-title>. <source>Brain J Neurol</source><year>2006</year>;<volume>129</volume>:<fpage>200</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awh680</pub-id><pub-id pub-id-type="pmid">16280350</pub-id></mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Md</surname><given-names>G</given-names></name><name name-style="western"><surname>Vn</surname><given-names>N</given-names></name><name name-style="western"><surname>Km</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A B-cell-homing chemokine made in lymphoid follicles activates Burkett&#8217;s lymphoma receptor-1</article-title>. <source>Nature</source><year>1998</year>;<volume>391</volume>:<fpage>799</fpage>-<lpage>803</lpage>.<pub-id pub-id-type="pmid">9486651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35876</pub-id></mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baay-Guzman</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Huerta-Yepez</surname><given-names>S</given-names></name><name name-style="western"><surname>Vega</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>Role of CXCL13 in asthma: novel therapeutic target</article-title>. <source>Chest</source><year>2012</year>;<volume>141</volume>:<fpage>886</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">22016489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.11-0633</pub-id></mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z-J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B-C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y-J</given-names></name></person-group>. <article-title>Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain</article-title>. <source>Cell Mol Life Sci</source><year>2017</year>;<volume>74</volume>:<fpage>3275</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28389721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-017-2513-1</pub-id><pub-id pub-id-type="pmcid">PMC11107618</pub-id></mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>X</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T</given-names></name><name name-style="western"><surname>Sathish</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Chronic inflammatory pain is associated with increased excitability and hyperpolarization-activated current (Ih) in C- but not A&#948;-nociceptors</article-title>. <source>Pain</source><year>2012</year>;<volume>153</volume>:<fpage>900</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22377439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2012.01.019</pub-id></mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramesh</surname><given-names>G</given-names></name><name name-style="western"><surname>Borda</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gill</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Possible role of glial cells in the onset and progression of lyme neuroborreliosis</article-title>. <source>J Neuroinflamm</source><year>2009</year>;<volume>6</volume>:<fpage>1</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-6-23</pub-id><pub-id pub-id-type="pmcid">PMC2748066</pub-id><pub-id pub-id-type="pmid">19706181</pub-id></mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narayan</surname><given-names>K</given-names></name><name name-style="western"><surname>Dail</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis</article-title>. <source>Ann Neurol</source><year>2005</year>;<volume>57</volume>:<fpage>813</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">15929033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20486</pub-id></mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsurui</surname><given-names>R</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H</given-names></name><name name-style="western"><surname>Natori</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Homeostatic signals, including IL-7 and self-MHC recognition, induce the development of peripheral helper T cells, which are enriched in the joints of rheumatoid arthritis</article-title>. <source>J Transl Autoimmun</source><year>2024</year>;<volume>9</volume>:<fpage>100258</fpage>.<pub-id pub-id-type="pmid">39554252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtauto.2024.100258</pub-id><pub-id pub-id-type="pmcid">PMC11567946</pub-id></mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>M</given-names></name><name name-style="western"><surname>Adah</surname><given-names>D</given-names></name><name name-style="western"><surname>Tariq</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>CXCL13/CXCR5 signaling axis in cancer</article-title>. <source>Life Sci</source><year>2019</year>;<volume>227</volume>:<fpage>175</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">31026453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2019.04.053</pub-id></mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammirante</surname><given-names>M</given-names></name><name name-style="western"><surname>Shalapour</surname><given-names>S</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts</article-title>. <source>Pnas</source><year>2014</year>;<volume>111</volume>:<fpage>14776</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">25267627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1416498111</pub-id><pub-id pub-id-type="pmcid">PMC4205637</pub-id></mixed-citation></ref><ref id="R57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghafouri-Fard</surname><given-names>S</given-names></name><name name-style="western"><surname>Abak</surname><given-names>A</given-names></name><name name-style="western"><surname>Bahroudi</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>The interplay between non-coding RNAs and twist1 signaling contribute to human disorders</article-title>. <source>Biomed Pharmacother</source><year>2021</year>;<volume>135</volume>:<fpage>111220</fpage>.<pub-id pub-id-type="pmid">33433357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111220</pub-id></mixed-citation></ref><ref id="R58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Long noncoding RNA SNHG5 knockdown alleviates neuropathic pain by targeting the miR-154-5p/CXCL13 axis</article-title>. <source>Neurochem Res</source><year>2020</year>;<volume>45</volume>:<fpage>1566</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">32248399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-020-03021-2</pub-id></mixed-citation></ref><ref id="R59"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>LncRNA NONRATT009773.2 promotes bone cancer pain progression through the miR-708-5p/CXCL13 axis</article-title>. <source>Eur J Neurosci</source><year>2022</year>;<volume>55</volume>:<fpage>661</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">35075718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejn.15607</pub-id></mixed-citation></ref><ref id="R60"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>H-L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y-Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P-M</given-names></name><etal/></person-group>. <article-title>The roles of chemokine CXCL13 in the development of bone cancer pain and the regulation of morphine analgesia in rats</article-title>. <source>Neurosci</source><year>2019</year>;<volume>406</volume>:<fpage>62</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2019.02.025</pub-id><pub-id pub-id-type="pmid">30826523</pub-id></mixed-citation></ref><ref id="R61"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X-B</given-names></name><name name-style="western"><surname>He</surname><given-names>L-N</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B-C</given-names></name><etal/></person-group>. <article-title>Increased CXCL13 and CXCR5 in anterior cingulate cortex contributes to neuropathic pain-related conditioned place aversion</article-title>. <source>Neurosci Bull</source><year>2019</year>;<volume>35</volume>:<fpage>613</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">31041693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12264-019-00377-6</pub-id><pub-id pub-id-type="pmcid">PMC6616612</pub-id></mixed-citation></ref><ref id="R62"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Tertiary lymphoid structures are linked to enhanced antitumor immunity and better prognosis in muscle-invasive bladder cancer</article-title>. <source>Adv Sci (Weinh)</source><year>2025</year>;<volume>12</volume>:<fpage>2410998</fpage>.<pub-id pub-id-type="pmid">39739621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202410998</pub-id><pub-id pub-id-type="pmcid">PMC11831474</pub-id></mixed-citation></ref><ref id="R63"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koga</surname><given-names>K</given-names></name><name name-style="western"><surname>Descalzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Coexistence of two forms of LTP in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain</article-title>. <source>Neuron</source><year>2015</year>;<volume>85</volume>:<fpage>377</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">25556835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2014.12.021</pub-id><pub-id pub-id-type="pmcid">PMC4364605</pub-id></mixed-citation></ref><ref id="R64"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Ko</surname><given-names>H-G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Alleviating neuropathic pain hypersensitivity by inhibiting PKMzeta in the anterior cingulate cortex</article-title>. <source>Science</source><year>2010</year>;<volume>330</volume>:<fpage>1400</fpage>&#8211;<lpage>04</lpage>.<pub-id pub-id-type="pmid">21127255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1191792</pub-id></mixed-citation></ref><ref id="R65"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>W</given-names></name><name name-style="western"><surname>Dan</surname><given-names>L</given-names></name><name name-style="western"><surname>Netra</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>A pharmaco-fMRI study on pain networks induced by electrical stimulation after sumatriptan injection</article-title>. <source>Exp Brain Res</source><year>2013</year>;<volume>226</volume>:<fpage>15</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">23329206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00221-013-3405-8</pub-id></mixed-citation></ref><ref id="R66"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex</article-title>. <source>Nat Commun</source><year>2018</year>;<volume>14</volume>:<fpage>3751</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-06295-x</pub-id><pub-id pub-id-type="pmcid">PMC6138720</pub-id><pub-id pub-id-type="pmid">30218052</pub-id></mixed-citation></ref><ref id="R67"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Ketamine and its two enantiomers in anesthesiology and psychiatry: a historical review and future directions</article-title>. <source>J Anesth Transl Med</source><year>2024</year>;<volume>3</volume>:<fpage>65</fpage>&#8211;<lpage>75</lpage>.</mixed-citation></ref><ref id="R68"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansen</surname><given-names>JP</given-names></name><name name-style="western"><surname>Fields</surname><given-names>HL</given-names></name><name name-style="western"><surname>Manning</surname><given-names>BH</given-names></name></person-group>. <article-title>The affective component of pain in rodents: direct evidence for a contribution of the anterior cingulate cortex</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2001</year>;<volume>98</volume>:<fpage>8077</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">11416168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.141218998</pub-id><pub-id pub-id-type="pmcid">PMC35470</pub-id></mixed-citation></ref><ref id="R69"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaGraize</surname><given-names>SC</given-names></name><name name-style="western"><surname>Borzan</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>YB</given-names></name><etal/></person-group>. <article-title>Selective regulation of pain affect following activation of the opioid anterior cingulate cortex system</article-title>. <source>Exp Neurol</source><year>2006</year>;<volume>197</volume>:<fpage>22</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">15996657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2005.05.008</pub-id></mixed-citation></ref><ref id="R70"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X-L</given-names></name><name name-style="western"><surname>Ou-Yang</surname><given-names>H-D</given-names></name><etal/></person-group>. <article-title>Epigenetic upregulation of CXCL12 expression mediates antitubulin chemotherapeutics-induced neuropathic pain</article-title>. <source>Pain</source><year>2017</year>;<volume>158</volume>:<fpage>637</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">28072604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000000805</pub-id></mixed-citation></ref><ref id="R71"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>CXCR5 down-regulation alleviates cognitive dysfunction in a mouse model of sepsis-associated encephalopathy: potential role of microglial autophagy and the p38MAPK/NF-&#954;B/STAT3 signaling pathway</article-title>. <source>J Neuroinflamm</source><year>2021</year>;<volume>18</volume>:<fpage>246</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02300-1</pub-id><pub-id pub-id-type="pmcid">PMC8554863</pub-id><pub-id pub-id-type="pmid">34711216</pub-id></mixed-citation></ref><ref id="R72"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z</given-names></name></person-group>. <article-title>Downregulating lncRNA PVT1 relieves astrocyte overactivation induced neuropathic pain through targeting miR-186-5p/CXCL13/CXCR5 axis</article-title>. <source>Neurochem Res</source><year>2021</year>;<volume>46</volume>:<fpage>1457</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">33742328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-021-03287-0</pub-id></mixed-citation></ref><ref id="R73"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ino</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>TSLP in DRG neurons causes the development of neuropathic pain through T cells</article-title>. <source>J Neuroinflamm</source><year>2023</year>;<volume>20</volume>:<fpage>200</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-023-02882-y</pub-id><pub-id pub-id-type="pmcid">PMC10474733</pub-id><pub-id pub-id-type="pmid">37660072</pub-id></mixed-citation></ref><ref id="R74"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection</article-title>. <source>J Hepatol</source><year>2020</year>;<volume>72</volume>:<fpage>420</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">31610223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2019.09.031</pub-id></mixed-citation></ref><ref id="R75"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Mechanism of IRF5-regulated CXCL13/CXCR5 signaling axis in CCI-induced neuropathic pain in rats</article-title>. <source>Curr Mol Med</source><year>2024</year>;<volume>24</volume>:<fpage>940</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">37622691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566524023666230825120836</pub-id></mixed-citation></ref><ref id="R76"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name></person-group>. <article-title>Emerging targets in neuroinflammation-driven chronic pain</article-title>. <source>Nat Rev Drug Discov</source><year>2024</year><volume>13</volume>:<fpage>533</fpage>-<lpage>48</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd4334</pub-id><pub-id pub-id-type="pmcid">PMC4228377</pub-id><pub-id pub-id-type="pmid">24948120</pub-id></mixed-citation></ref><ref id="R77"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johannes</surname><given-names>CB</given-names></name><name name-style="western"><surname>Le</surname><given-names>TK</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The prevalence of chronic pain in United States adults: results of an internet-based survey</article-title>. <source>J Pain</source><year>2010</year>;<volume>11</volume>:<fpage>1230</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">20797916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2010.07.002</pub-id></mixed-citation></ref><ref id="R78"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases</article-title>. <source>Cell Mol Biol Lett</source><year>2024</year>;<volume>29</volume>:<fpage>134</fpage>.<pub-id pub-id-type="pmid">39472796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s11658-024-00653-y</pub-id><pub-id pub-id-type="pmcid">PMC11523778</pub-id></mixed-citation></ref><ref id="R79"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></name><name name-style="western"><surname>Grebely</surname><given-names>J</given-names></name><name name-style="western"><surname>Stone</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Global patterns of opioid use and dependence: harms to populations, interventions, and future action</article-title>. <source>Lancet</source><year>2019</year>;<volume>394</volume>:<fpage>1560</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">31657732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32229-9</pub-id><pub-id pub-id-type="pmcid">PMC7068135</pub-id></mixed-citation></ref><ref id="R80"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>LR</given-names></name><name name-style="western"><surname>Maier</surname><given-names>SF</given-names></name></person-group>. <article-title>Glia: a novel drug discovery target for clinical pain</article-title>. <source>Nat Rev Drug Discov</source><year>2003</year>;<volume>2</volume>:<fpage>973</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">14654796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd1251</pub-id></mixed-citation></ref><ref id="R81"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>RR</given-names></name><name name-style="western"><surname>Berta</surname><given-names>T</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group>. <article-title>Glia and pain: is chronic pain a gliopathy?</article-title><source>Pain</source><year>2013</year>;<volume>154</volume>:<fpage>S10</fpage>-<lpage>28</lpage>.<pub-id pub-id-type="pmid">23792284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2013.06.022</pub-id><pub-id pub-id-type="pmcid">PMC3858488</pub-id></mixed-citation></ref><ref id="R82"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sha</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Directions for analgesic development</article-title>. <source>J Anesth Transl Med</source><year>2024</year>;<volume>3</volume>:<fpage>87</fpage>&#8211;<lpage>95</lpage>.</mixed-citation></ref><ref id="R83"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ririe</surname><given-names>DG</given-names></name><name name-style="western"><surname>Eisenach</surname><given-names>JC</given-names></name></person-group>. <article-title>Age-dependent responses to nerve injury-induced mechanical allodynia</article-title>. <source>Anesthesiol</source><year>2006</year>;<volume>104</volume>:<fpage>344</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200602000-00021</pub-id><pub-id pub-id-type="pmid">16436855</pub-id></mixed-citation></ref><ref id="R84"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amir</surname><given-names>R</given-names></name><name name-style="western"><surname>Argoff</surname><given-names>CE</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>GJ</given-names></name><etal/></person-group>. <article-title>The role of sodium channels in chronic inflammatory and neuropathic pain</article-title>. <source>J Pain</source><year>2006</year>;<volume>7</volume>:<fpage>S1</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2006.01.444</pub-id><pub-id pub-id-type="pmid">16632328</pub-id></mixed-citation></ref><ref id="R85"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walco</surname><given-names>GA</given-names></name><name name-style="western"><surname>Dworkin</surname><given-names>RH</given-names></name><name name-style="western"><surname>Krane</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>Neuropathic pain in children: special considerations</article-title>. <source>Mayo Clin Proc</source><year>2010</year>;<volume>85</volume>:<fpage>S33</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">20194147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4065/mcp.2009.0647</pub-id><pub-id pub-id-type="pmcid">PMC2844006</pub-id></mixed-citation></ref><ref id="R86"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Km</surname><given-names>A</given-names></name><name name-style="western"><surname>Rb</surname><given-names>H</given-names></name><name name-style="western"><surname>Jg</surname><given-names>C</given-names></name></person-group>. <article-title>CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity</article-title>. <source>Immunity</source><year>2002</year>;<volume>16</volume>:<fpage>67</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">11825566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1074-7613(01)00257-6</pub-id></mixed-citation></ref><ref id="R87"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woolf</surname><given-names>CJ</given-names></name></person-group>. <article-title>Overcoming obstacles to developing new analgesics</article-title>. <source>Nat Med</source><year>2010</year>;<volume>16</volume>:<fpage>1241</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">20948534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2230</pub-id></mixed-citation></ref><ref id="R88"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Js</surname><given-names>M</given-names></name></person-group>. <article-title>Animal models of pain: progress and challenges</article-title>. <source>Nat Rev Neurosci</source><year>2009</year>;<volume>10</volume>:<fpage>283</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="pmid">19259101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2606</pub-id></mixed-citation></ref><ref id="R89"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>T</given-names></name><name name-style="western"><surname>Vera-Portocarrero</surname><given-names>L</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Unmasking the tonic-aversive state in neuropathic pain</article-title>. <source>Nat Neurosci</source><year>2009</year>;<volume>12</volume>:<fpage>1364</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">19783992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.2407</pub-id><pub-id pub-id-type="pmcid">PMC3427725</pub-id></mixed-citation></ref><ref id="R90"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Sodium channels as a new target for pain treatment</article-title>. <source>Front Pharmacol</source><year>2025</year>;<volume>16</volume>:<fpage>1573254</fpage>.<pub-id pub-id-type="pmid">40206072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1573254</pub-id><pub-id pub-id-type="pmcid">PMC11979154</pub-id></mixed-citation></ref><ref id="R91"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orr</surname><given-names>B</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Phase I trial combining chemokine-targeting with loco-regional chemoimmunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity</article-title>. <source>Clin Cancer Res Off J Am Assoc Cancer Res</source><year>2022</year>;<volume>28</volume>:<fpage>2038</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-3659</pub-id><pub-id pub-id-type="pmcid">PMC9106847</pub-id><pub-id pub-id-type="pmid">35046055</pub-id></mixed-citation></ref><ref id="R92"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>S-X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y-G</given-names></name><name name-style="western"><surname>Ding</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Dynamic analysis of intrahepatic T cells reveals a unique group of restorative Cxcr3+ tissue-resident CD4 T cells in acute liver injury</article-title>. <source>Toxicology</source><year>2025</year>;<volume>511</volume>:<fpage>154058</fpage>.<pub-id pub-id-type="pmid">39828240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tox.2025.154058</pub-id></mixed-citation></ref><ref id="R93"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A global regulatory network for dysregulated gene expression and abnormal metabolic signaling in immune cells in the microenvironment of graves</article-title>. <source>Disease and Hashimoto&#8217;s Thyroid Front Immunol</source><year>2022</year>;<volume>13</volume>:<fpage>879824</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.879824</pub-id><pub-id pub-id-type="pmcid">PMC9204353</pub-id><pub-id pub-id-type="pmid">35720300</pub-id></mixed-citation></ref><ref id="R94"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crecelius</surname><given-names>JM</given-names></name><name name-style="western"><surname>Manz</surname><given-names>AR</given-names></name><name name-style="western"><surname>Benzow</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Receptor determinants for &#946;-arrestin functional specificity at C-X-C chemokine receptor 5</article-title>. <source>Mol Pharmacol</source><year>2024</year>;<volume>106</volume>:<fpage>287</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">39472027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/molpharm.124.000942</pub-id><pub-id pub-id-type="pmcid">PMC11585254</pub-id></mixed-citation></ref><ref id="R95"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Z-H</given-names></name><name name-style="western"><surname>Song</surname><given-names>X-J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C-L</given-names></name><etal/></person-group>. <article-title>Up-regulation of microglial chemokine CXCL12 in anterior cingulate cortex mediates neuropathic pain in diabetic mice</article-title>. <source>Acta Pharmacol Sin</source><year>2023</year>;<volume>44</volume>:<fpage>1337</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">36697977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-022-01046-7</pub-id><pub-id pub-id-type="pmcid">PMC10310783</pub-id></mixed-citation></ref><ref id="R96"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>S-Z</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M-J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y-M</given-names></name><etal/></person-group>. <article-title>Elevated plasma CXCL12 leads to pain chronicity via positive feedback upregulation of CXCL12/CXCR4 axis in pain synapses</article-title>. <source>J Headache Pain</source><year>2024</year>;<volume>25</volume>:<fpage>1</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">39627724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-024-01917-w</pub-id><pub-id pub-id-type="pmcid">PMC11616163</pub-id></mixed-citation></ref><ref id="R97"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>TTQ</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C-P</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y-H</given-names></name><etal/></person-group>. <article-title>Enhanced CXCL10 expression in mast cells for cutaneous neurofibroma presenting with pain and itch</article-title>. <source>Br J Cancer</source><year>2025</year>;<volume>132</volume>:<fpage>611</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">39979642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-025-02956-z</pub-id><pub-id pub-id-type="pmcid">PMC11961721</pub-id></mixed-citation></ref><ref id="R98"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Stromal cell-derived factor 1 increases tetrodotoxin-resistant sodium currents Nav1.8 and Nav1.9 in rat dorsal root ganglion neurons via different mechanisms</article-title>. <source>Neurochem Res</source><year>2016</year>;<volume>41</volume>:<fpage>1587</fpage>&#8211;<lpage>603</lpage>.<pub-id pub-id-type="pmid">27038931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-016-1873-5</pub-id></mixed-citation></ref><ref id="R99"><label>[99]</label><mixed-citation publication-type="paper"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z-Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z-W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S-W</given-names></name><etal/></person-group><article-title>CXCL12/CXCR4 signaling contributes to neuropathic pain via central sensitization mechanisms in a rat spinal nerve ligation model</article-title>. <source>CNS Neurosci. Ther</source>. <year>2019</year>; <fpage>922</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">30955244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.13128</pub-id><pub-id pub-id-type="pmcid">PMC6698967</pub-id></mixed-citation></ref><ref id="R100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W-J</given-names></name><etal/></person-group>. <article-title>SDF1-CXCR4 signaling contributes to the transition from acute to chronic pain state</article-title>. <source>Mol Neurobiol</source><year>2017</year>;<volume>54</volume>:<fpage>2763</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">27011380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-016-9875-5</pub-id></mixed-citation></ref><ref id="R101"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Midavaine</surname><given-names>&#201;</given-names></name><name name-style="western"><surname>Brouillette</surname><given-names>RL</given-names></name><name name-style="western"><surname>Th&#233;berge</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Discovery of a CCR2-targeting pepducin therapy for chronic pain</article-title>. <source>Pharmacol Res</source><year>2024</year>;<volume>205</volume>:<fpage>107242</fpage>.<pub-id pub-id-type="pmid">38823470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2024.107242</pub-id></mixed-citation></ref><ref id="R102"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase II trial</article-title>. <source>Nat Commun</source><year>2025</year>;<volume>16</volume>:<fpage>1</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">40295492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-59004-w</pub-id><pub-id pub-id-type="pmcid">PMC12037888</pub-id></mixed-citation></ref><ref id="R103"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L-Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W-S</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Plasma proteomics identify novel biomarkers and dynamic patterns of biological aging</article-title>. <source>J Adv Res</source><year>2025</year>. doi:<pub-id pub-id-type="doi">10.1016/j.jare.2025.05.004</pub-id>.<pub-id pub-id-type="pmid">40328427</pub-id></mixed-citation></ref><ref id="R104"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer</article-title>. <source>J Immunother Cancer</source><year>2025</year>;<volume>13</volume>:<fpage>e010365</fpage>.<pub-id pub-id-type="pmid">40280564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2024-010365</pub-id><pub-id pub-id-type="pmcid">PMC12035477</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>